Healthcare Industry News: ACADIA Pharmaceuticals
News Release - August 19, 2013
ACADIA Pharmaceuticals Announces Appointment of Terrence Moore as Executive Vice President and Chief Commercial OfficerSAN DIEGO--(Healthcare Sales & Marketing Network)--ACADIA Pharmaceuticals Inc. (ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, announced the appointment of Terrence Moore as Executive Vice President and Chief Commercial Officer, effective today. Mr. Moore reports to ACADIA’s Chief Executive Officer, Uli Hacksell, Ph.D., and will be responsible for leading ACADIA’s commercial activities.
“Terry is an exceptional individual who brings a wealth of commercial experience to ACADIA from a variety of senior roles at several leading pharmaceutical companies. He has made key contributions to the building of multi-billion dollar brands in the CNS field, including Prozac®, Zyprexa®, Risperdal®, and Effexor XR®,” said Dr. Hacksell. “Terry’s marketing expertise and demonstrated ability to execute will help position ACADIA for success in the planned launch of pimavanserin in Parkinson’s disease psychosis and for effective life cycle management in order to maximize pimavanserin’s commercial potential.”
Mr. Moore has more than 25 years of experience as a senior member of sales and marketing teams at several pharmaceutical companies. Most recently, Mr. Moore was a principal of Cook-Moore Consulting and, before founding the firm, served as Vice President at Transcept Pharmaceuticals, where he was responsible for commercial strategy, business development and commercial alliance activities. Previously, Mr. Moore served as Vice President, U.S. Head of Neuroscience Marketing at Organon BioSciences and was responsible for the creation and building of its Neuroscience Business Unit. He also served as Vice President, U.S. Marketing, Effexor XR®, as well as Vice President, Global Strategy Depression Portfolio at Wyeth Pharmaceuticals. Earlier, Mr. Moore held senior management positions at Johnson & Johnson, where he helped to launch Risperdal® for additional indications in the U.S., and at Eli Lilly, where he held various sales and marketing roles over 11 years, including Zyprexa® Brand Manager.
Mr. Moore holds a B.S. degree in Pharmacy from the University of Florida, a B.A. degree in Chemistry from the University of South Florida and has completed executive development programs at the Kellogg School of Management and Wharton School of Business.
“I am very pleased to be joining an organization dedicated to meeting the needs of patients suffering from neurological disorders and those who are responsible for providing their care,” said Mr. Moore. “It is an exciting time at ACADIA as the company advances toward an NDA submission for pimavanserin and accelerates its pre-commercial activities. I look forward to working with the ACADIA team to achieve the goal of bringing this innovative product to market and building a successful pimavanserin franchise."
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders. ACADIA has a pipeline of product candidates led by pimavanserin, which is in Phase III development as a potential first-in-class treatment for Parkinson's disease psychosis. ACADIA also has clinical-stage programs for chronic pain and glaucoma in collaboration with Allergan, Inc. and two advanced preclinical programs directed at Parkinson’s disease and other neurological disorders. All product candidates are small molecules that emanate from discoveries made at ACADIA. ACADIA maintains a website at www.acadia-pharm.com to which ACADIA regularly posts copies of its press releases as well as additional information and through which interested parties can subscribe to receive email alerts.
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include but are not limited to statements related to the progress and timing of ACADIA’s drug discovery and development programs, either alone or with a partner, including clinical trials, the benefits to be derived from ACADIA’s product candidates, including pimavanserin, the timing of an NDA submission for pimavanserin, the timing of pre-commercial and commercial activities, the expected contributions of Mr. Moore to ACADIA’s business, the success of any launch, the life cycle management or commercial potential of pimavanserin, or the ability to create a pimavanserin franchise. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery, development and commercialization, and collaborations with others, building and maintaining a commercial organization and the fact that past results of clinical trials may not be indicative of future trial results. For a discussion of these and other factors, please refer to ACADIA’s annual report on Form 10-K for the year ended December 31, 2012 as well as ACADIA’s subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and ACADIA undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.
Source: ACADIA Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.